Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab versus placebo as adjuvant therapy after cystectomy in ctDNA-positive high-risk muscle-invasive bladder cancer
CTR20212032Phase 3Active
- Sponsor
- Roche
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bladder cancer and transitional cell carcinoma (TCC) comparing Atezolizumab with Placebo (2 arms). Primary endpoint: Disease-free survival in ctDNA-positive patients within 20 weeks after cystectomy. Started Mar 2022; status: active.
02
Drugs
atezolizumab
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20212032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212032.